Intact parathyroid hormone levels and primary hyperparathyroidism.

Metabolic syndrome is a cluster of conditions that increase cardiovascular risk. Prior research has shown that primary hyperparathyroidism (PHPT) can influence metabolic parameters. However, the role of intact parathyroid hormone (iPTH) levels in shaping these associations remains unclear. Established knowledge includes the link between PHPT and altered calcium metabolism. No prior work had resolved how varying iPTH levels might affect lipid profiles or vitamin D status in PHPT patients. This gap motivated a closer examination of iPTH's role in metabolic outcomes. PHPT patients exhibit diverse clinical presentations, but the relationship between iPTH and metabolic syndrome markers is not well defined. This paper's contribution lies in comparing clinical and lab data across iPTH levels. The study provides insights into how iPTH may influence metabolic syndrome components.

This study aimed to compare clinical features and metabolic syndrome indicators between PHPT patients with different serum iPTH levels. The specific problem addressed is the lack of clarity about how iPTH levels influence metabolic parameters in PHPT. The motivation stems from the need to better understand the relationship between iPTH and metabolic syndrome components such as triglycerides and HDL. The authors sought to determine if iPTH levels correlate with adenoma weight and other lab values. By analyzing these associations, the study aimed to inform PHPT management strategies. The hypothesis was that higher iPTH levels would show distinct metabolic profiles. This approach could help identify patients at greater risk for metabolic complications. The findings may guide targeted interventions for PHPT patients.

The study used a retrospective chart review of 212 PHPT patients. Participants were divided into two groups based on initial serum iPTH levels. One group had iPTH levels below 140 pg/mL, while the other had iPTH levels of 140 pg/mL or higher. Clinical characteristics and laboratory values were compared using Student's t-tests. Pearson's correlation coefficients were calculated to evaluate associations between variables. Adenoma weights were measured and compared between the groups. The study focused on metabolic syndrome indicators such as calcium, vitamin D, and lipid levels. This approach allowed the researchers to assess how iPTH levels influence these parameters in PHPT patients.

Patients in the higher iPTH group were younger and had elevated serum calcium and alkaline phosphatase levels. They also showed lower 25(OH)-vitamin D and HDL levels compared to the lower iPTH group. Adenoma weights were greater in the higher iPTH group. The iPTH level was positively correlated with adenoma weight, serum calcium, and triglyceride levels. It was negatively correlated with HDL levels. These findings suggest a link between iPTH and metabolic syndrome components. The strongest result was the association between iPTH and triglycerides and HDL. These correlations were statistically significant and consistent with the study's hypothesis.

The study supports the idea that iPTH levels are associated with triglyceride and HDL levels in PHPT patients. The authors propose that iPTH should be considered in the management of PHPT due to its metabolic implications. The findings suggest that higher iPTH levels correlate with specific metabolic changes. These correlations were observed in calcium, vitamin D, and lipid profiles. The study does not claim causality but highlights the importance of iPTH in PHPT management. The authors do not suggest new drug targets or future directions beyond their stated implications. The results indicate that iPTH levels may influence metabolic syndrome markers. These findings may help guide clinical decisions in PHPT patients.